- GeoVax Labs Inc GOVX has revealed updates about its next-generation COVID-19 vaccine, GEO-CM04S1, which has shown promising results in a single dose, including preliminary data from an ongoing phase 2 trial.
- The results were presented at the Vaccines Summit Boston 2023 and the Congress for the International Society for the Advancement of Cytometry 2023 meetings.
- According to the preliminary analysis, CM04S1 is highly immunogenic as it has induced both antibody and T-cell responses, including neutralizing antibodies.
- The positive results support the planned progression of the phase 2 study, which includes a direct comparison with currently approved mRNA vaccines.
- A second phase 2 trial for CM04S1 is underway to measure its effectiveness as a booster for healthy patients who have already received the Pfizer or Moderna mRNA vaccine.
- These studies will form the basis for comparing vaccine potential in various patient groups and the general population.
- CM04S1 is a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector platform that presents multiple vaccine antigens in a single dose.
- It features both the spike and nucleocapsid antigens of SARS-CoV-2 and is specifically designed to induce antibody and T-cell responses to the non-variable parts of the virus.
- Based on animal models and the completed phase 1 study, vaccine-induced immune responses can recognize both early and later variants, including the Omicron Variant.
- This type of vaccine may not require repeated modification and updating.
- Price Action: GOVX shares rose 4.22% to $0.69 at the last check on Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
